Mechelen, Belgium; 19 April 2007 - Galapagos NV (Euronext & LSE: GLPG) announced today that its service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca (LSE, NYSE, OMX: AZN), a global pharmaceutical leader. This is the second program between the two companies under an agreement signed in August 2006. In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry and supporting biology and ADMET services for an AstraZeneca drug discovery program. Total contract value for Galapagos is EUR 620,000.
